📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
India Glycols: ₹191.76 Cr Fine Set Aside; Penalty Reduced to ₹41 Cr in Customs Case
India Glycols Limited has received a favorable appellate order regarding a customs duty dispute from March 2024. The Appellate Authority has set aside a massive redemption fine of ₹191.76 crore and reduced the penalty from ₹82 crore to ₹41 crore. While the core duty demand of ₹33.43 crore plus interest remains upheld, the total potential liability has decreased significantly. The company intends to file a second appeal to contest the remaining confirmed amounts.
Key Highlights
Redemption fine of ₹191.76 crore has been completely set aside by the Appellate Authority.
Penalty amount reduced by 50%, from ₹82 crore down to ₹41 crore.
Customs duty demand of ₹33.43 crore plus applicable interest remains upheld.
Company plans to file a second appeal against the remaining ₹74.43 crore (duty + penalty) plus interest.
💼 Action for Investors
Investors should view this as a positive development as it significantly reduces a major contingent liability, though the remaining ₹74.43 crore plus interest should still be monitored through the next appeal phase.
CARE Places India Glycols on Rating Watch with Developing Implications Amid Demerger Plans
CARE Ratings has placed India Glycols' 'CARE A-' long-term rating on 'Rating Watch with Developing Implications' due to the proposed demerger of its Biofuel, Potable Spirits, and Bio-pharma businesses. The company's financial profile is improving, supported by a ₹467 crore preferential issue in Q3FY26 which was primarily used for debt reduction. Performance for 9MFY26 shows 11% revenue growth to ₹3,239 crore with margins expanding to 15.04%. The restructuring is expected to be completed within six months, resulting in three separate entities to enhance management focus.
Key Highlights
CARE A- rating placed on 'Rating Watch with Developing Implications' following the board-approved composite scheme of arrangement.
Raised ₹467 crore via preferential issue in Q3FY26, reducing total debt including LC acceptances to ₹1,793 crore as of January 2026.
9MFY26 revenue grew 11% YoY to ₹3,239 crore with PBILDT margins expanding significantly to 15.04%.
Net debt to PBILDT ratio is projected to improve to 2.5x-3.0x by FY26-end from 4.31x in FY25.
Demerger will split operations into IGL (Chemicals), IGL Spirits (Biofuels/Spirits), and Ennature Bio Pharma (Nutraceuticals).
💼 Action for Investors
Investors should maintain a watch on the NCLT approval process for the demerger, which is expected to unlock value across different business segments. The substantial debt reduction and improving margins provide a positive cushion during this transition period.
India Glycols Board to Meet on March 17 to Consider Interim Dividend for FY 2025-26
India Glycols Limited has scheduled a Board of Directors meeting on March 17, 2026, to consider the declaration of an interim dividend for the financial year 2025-26. Following this announcement, the company has implemented a trading window closure for insiders from March 11 to March 19, 2026. This move indicates a potential cash payout to shareholders, reflecting the company's current financial health and commitment to returning value. Investors should watch for the specific dividend amount and record date following the meeting.
Key Highlights
Board meeting scheduled for March 17, 2026, to consider interim dividend for FY 2025-26
Trading window for securities closed from March 11, 2026, to March 19, 2026
Meeting convened under Regulation 29 of SEBI (LODR) Regulations, 2015
The outcome of the meeting will determine the dividend payout ratio for the current fiscal year
💼 Action for Investors
Investors should monitor the March 17 board meeting outcome for the dividend amount and record date to assess the yield. Existing shareholders may benefit from the potential payout, while new investors should evaluate the stock's valuation relative to the dividend.
India Glycols Schedules NCLT-Convened Creditors Meeting for Demerger on March 24, 2026
India Glycols Limited (IGL) is progressing with its corporate restructuring plan to demerge businesses into Ennature Biopharma Limited and IGL Spirits Limited. Following orders from the NCLT Allahabad Bench, the company has scheduled a meeting of its unsecured creditors on March 24, 2026, to seek approval for the Scheme of Arrangement. This follows similar procedural steps for shareholders and is a mandatory regulatory requirement for the demerger to proceed. The remote e-voting for eligible creditors is set to take place between March 20 and March 23, 2026.
Key Highlights
NCLT-convened meeting of unsecured creditors scheduled for March 24, 2026, via Video Conferencing.
Scheme involves the demerger of units into two resulting companies: Ennature Biopharma Limited and IGL Spirits Limited.
Remote e-voting period is set from March 20, 2026 (9:00 AM) to March 23, 2026 (5:00 PM).
The cut-off date for determining the eligibility of unsecured creditors to vote was November 15, 2025.
💼 Action for Investors
Investors should track the outcome of these meetings as the demerger will lead to the creation of specialized entities for biopharma and spirits. No immediate action is required, but the restructuring is a key milestone for potential value unlocking.
India Glycols Schedules NCLT-Convened Meeting on March 24, 2026, for Business Demerger
India Glycols Limited (IGL) has announced a Court Convened Meeting on March 24, 2026, to seek shareholder approval for a major Scheme of Arrangement. The plan involves demerging specific business undertakings into two new entities: Ennature Biopharma Limited and IGL Spirits Limited. Shareholders as of the cut-off date of March 17, 2026, will be eligible to vote on the proposal. This restructuring is intended to streamline operations and potentially unlock value for shareholders by creating focused business units.
Key Highlights
NCLT-convened meeting for equity shareholders scheduled for March 24, 2026, at 11:00 A.M. via video conferencing.
Proposed demerger of business segments into Ennature Biopharma Limited and IGL Spirits Limited.
Remote e-voting period is set from March 20, 2026, to March 23, 2026, with a cut-off date of March 17, 2026.
The scheme has already received 'No-objection' from NSE and 'No adverse observation' from BSE as of November 2025.
Special purpose financial statements for the period ending September 30, 2025, have been prepared for all involved entities.
💼 Action for Investors
Investors should monitor the demerger ratio and the specific assets being transferred to evaluate the long-term value of the new entities. Shareholders are advised to participate in the e-voting process to support the corporate restructuring.
India Glycols Reschedules NCLT-Directed Shareholder Meeting to March 24, 2026
India Glycols Limited has received a revised order from the NCLT Allahabad Bench regarding its proposed Scheme of Arrangement involving Ennature Biopharma and IGL Spirits. The meetings for equity shareholders and unsecured creditors, originally set for March 9, 2026, have been rescheduled to March 24, 2026. This administrative change was necessitated by the unavailability of the NCLT-appointed Chairperson on the original date. The meetings will be conducted via video conferencing to consider and approve the restructuring scheme.
Key Highlights
NCLT Allahabad Bench approved rescheduling of shareholder and creditor meetings to March 24, 2026.
The original meeting date was March 9, 2026, but was changed due to the Chairperson's unavailability.
The Scheme of Arrangement involves India Glycols, Ennature Biopharma Limited, and IGL Spirits Limited.
Meetings will be held via video conferencing under Sections 230 to 232 of the Companies Act, 2013.
The rest of the NCLT order dated January 15, 2026, remains unchanged and valid.
💼 Action for Investors
Investors should mark the new date of March 24, 2026, to participate in the voting process for the proposed demerger and arrangement. This is a routine administrative delay and does not reflect on the merits of the underlying transaction.
India Glycols Q3FY26 Net Profit Rises 19% to ₹68 Cr; EBITDA Margins Expand to 16%
India Glycols reported a strong Q3FY26 with net revenue growing 13% YoY to ₹1,102 crore and EBITDA surging 36% to ₹176 crore. The company achieved a significant debt reduction of ₹582 crore, primarily through a preferential allotment, which is expected to lower interest costs significantly from Q4 onwards. Segmental performance was robust, particularly in Bio-Fuels where revenue jumped 45% and Bio-Based Specialties where EBIT margins expanded to 12.8%. The Potable Spirits division continues its premiumization strategy through the Amrut partnership and expansion into new markets like Kerala and CSD.
Key Highlights
Consolidated Net Revenue for Q3FY26 grew 13% YoY to ₹1,102 Cr, while 9M PAT rose 23.4% to ₹206 Cr.
EBITDA margins expanded by 277 bps YoY to 16.0% in Q3, driven by operational efficiencies and high-margin product focus.
Total debt reduced by ₹582 Cr (₹467 Cr via preferential allotment), which will significantly reduce finance costs in future quarters.
Bio-Fuel segment revenue surged 45.2% YoY to ₹394 Cr in Q3, supported by India's 20% ethanol blending target.
Potable Spirits segment achieved 9M revenue of ₹1,025 Cr with a healthy EBIT margin of 21.2%.
💼 Action for Investors
Investors should note the substantial debt reduction and margin expansion as key drivers for future profitability. The company's strategic shift toward premium spirits and high-margin specialty chemicals makes it a strong candidate for long-term growth.
India Glycols Q3 PAT Jumps 49% YoY to ₹65.26 Cr; Bio-Fuel Segment Revenue Grows 45%
India Glycols Limited (IGL) reported a robust performance for Q3 FY26, with standalone Net Profit rising 48.8% YoY to ₹65.26 crore. Revenue from operations increased 5.25% YoY to ₹2,551.06 crore, significantly supported by a 45% surge in the Bio-Fuel segment revenue. The company is actively pursuing a demerger of its Bio Pharma and Spirits & Biofuel undertakings into separate listed entities, with an appointed date of April 1, 2026. Furthermore, IGL strengthened its capital base by raising approximately ₹467 crore through a preferential allotment at ₹915 per share during the quarter.
Key Highlights
Standalone Net Profit (PAT) grew 48.8% YoY to ₹65.26 crore vs ₹43.84 crore in the previous year.
Bio-Fuel segment revenue surged 45% YoY to ₹394.28 crore from ₹271.54 crore.
Profit Before Tax (PBT) increased 51% YoY to ₹88.30 crore despite a ₹0.83 crore exceptional charge related to new labour codes.
Completed a preferential allotment of 51.03 lakh shares at ₹915 per share, raising ₹466.99 crore.
The demerger process is on track with the NCLT Allahabad Bench allowing the first motion application on January 15, 2026.
💼 Action for Investors
Investors should monitor the upcoming demerger as a major value-unlocking event and track the continued high growth in the Bio-Fuel segment. The recent fundraise at ₹915 per share indicates strong institutional confidence and provides a valuation benchmark for the current market price.
India Glycols Receives NCLT Approval for First Motion of Three-Way Demerger Scheme
India Glycols Limited has received NCLT approval for the first motion of its scheme to demerge its 'Bio Pharma' and 'Spirits and Biofuel' undertakings into two separate entities, Ennature Biopharma and IGL Spirits. The NCLT has ordered meetings for equity shareholders and unsecured creditors while dispensing with meetings for secured creditors who provided 95.46% consent. Both resulting companies are intended to be listed on the NSE and BSE, aiming to unlock value and provide management focus for each distinct business segment. The appointed date for this restructuring is set for April 1, 2026.
Key Highlights
NCLT Allahabad Bench allowed the first motion for demerging Bio Pharma and Spirits & Biofuel units.
Secured creditors' meeting dispensed with after obtaining 95.46% consent in value.
Resulting entities, Ennature Biopharma and IGL Spirits, are planned to be listed on NSE and BSE.
The appointed date for the proposed Scheme of Arrangement is set as April 1, 2026.
Equity shareholders of resulting companies provided 99.94% consent, leading to meeting dispensation.
💼 Action for Investors
Investors should maintain a positive outlook as the demerger is likely to unlock value by creating specialized, listed entities for the biopharma and spirits businesses. Monitor the upcoming shareholder and creditor meetings for the final approval stages.
India Glycols: CGST Appeal Allowed, ₹1,92,12,510 Demand Dropped
India Glycols Limited received a favorable order from the Commissioner, CGST (Appeals), Noida, setting aside the earlier demand order issued by the Joint Commissioner, CGST, Noida. The original order had disallowed Transitional Input Tax Credit (ITC) and demanded ₹1,92,12,510 along with equivalent penalty and applicable interest. With the appeal being allowed, the demand for tax, penalty, and interest now stands dropped, resulting in no financial impact on the company.
Key Highlights
Demand of ₹1,92,12,510 for disallowed Transitional Input Tax Credit (ITC) dropped.
Order dated 28th January 2025 passed by Joint Commissioner, CGST, Noida, was set aside.
Appeal allowed by Commissioner, CGST (Appeals), Noida on 26th November 2025.
Order received by the company on 4th December, 2025.
💼 Action for Investors
This is a positive development as it removes a contingent liability of ₹1,92,12,510. Investors can view this as a reduction in potential financial risk for India Glycols.